Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Comparison of Total Body Irradiation (TBI) Conditioning with non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T and NK-cell Non-Hodgkin Lymphoma.

Maeng CH, Ko YH, Lim DH, Kang ES, Choi JY, Kim WS, Kim SJ.

Cancer Res Treat. 2016 May 9. doi: 10.4143/crt.2015.476. [Epub ahead of print]

2.

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.

Maeng CH, Ahn SW, Ryu SY, Han S, Ko YH, Ji JH, Kim WS, Kim SJ.

Korean J Intern Med. 2016 May;31(3):560-9. doi: 10.3904/kjim.2014.222. Epub 2016 Feb 22.

3.

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.

Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim do H, Won YW, Ji JH, Kim HS, Rha SY, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.

Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10.

4.
5.

Thyroid cancer and T lymphoblastic leukemia in Crohn disease: a case report and literature review.

Byun JM, Baek SK, Yoon HJ, Kim SY, Maeng CH, Park TS, Kim HJ, Choi YY, Um YJ.

Lab Med. 2015 Spring;46(2):140-5. doi: 10.1309/LMU4KMJDRM3AD6FQ. Review.

6.

Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication.

Jyothi KR, Beloor J, Jo A, Nguyen MN, Choi TG, Kim JH, Akter S, Lee SK, Maeng CH, Baik HH, Kang I, Ha J, Kim SS.

Int J Nanomedicine. 2015 Jan 30;10:903-21. doi: 10.2147/IJN.S74723. eCollection 2015.

7.

Radiation recall phenomenon presenting as myositis triggered by carboplatin plus paclitaxel and related literature review.

Maeng CH, Park JS, Lee SA, Kim DH, Yun DH, Yoo SD, Kim HS, Chon J.

J Cancer Res Ther. 2014 Oct-Dec;10(4):1093-7. doi: 10.4103/0973-1482.146090. Review.

8.

Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea.

Kim MJ, Hong ME, Maeng CH, Jung HA, Hong JY, Choi MK, Kim SJ, Ko YH, Kim WS.

Int J Hematol. 2015 Mar;101(3):273-8. doi: 10.1007/s12185-014-1728-2. Epub 2015 Jan 1.

PMID:
25552248
9.

Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer.

Jung HA, Kim HJ, Maeng CH, Park SH, Lee J, Park JO, Park YS, Lim HY, Kang WK.

Cancer Res Treat. 2015 Jan;47(1):72-7. doi: 10.4143/crt.2013.172. Epub 2014 Aug 21.

10.

Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.

Kim SJ, Cheong JW, Kim DY, Lee JH, Lee KH, Kim YK, Kim HJ, Song IC, Jo DY, Lee JO, Bang SM, Park J, Lee JH, Lee WS, Joo YD, Maeng CH, Yoon HJ, Lee NR, Kwak JY, Kim KH, Won JH, Han BR, Zang DY, Moon JH, Sohn SK, Bae SH, Ryoo HM, Kim SY, Lee MH, Min YH; Korean Society of Hematology AML/MDS Working Party.

Int J Hematol. 2014 Aug;100(2):141-51. doi: 10.1007/s12185-014-1617-8. Epub 2014 Jul 5.

PMID:
24996615
11.

Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.

Jung HA, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.

Anticancer Res. 2014 Feb;34(2):1037-45.

PMID:
24511052
12.

Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma.

Jung HA, Adenis A, Lee J, Park SH, Maeng CH, Park S, Ahn HK, Shim YM, Penel N, Im YH.

Cancer Res Treat. 2013 Dec;45(4):285-94. doi: 10.4143/crt.2013.45.4.285. Epub 2013 Dec 31.

13.

The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases.

Hong JY, Hong ME, Choi MK, Kim YS, Chang W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, Jung SH, Kim SJ, Ko YH, Kim WS.

Ann Oncol. 2014 Jan;25(1):182-8. doi: 10.1093/annonc/mdt530.

14.

Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients.

Park S, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.

Acta Haematol. 2014;131(4):193-9. doi: 10.1159/000354839. Epub 2013 Nov 26.

PMID:
24296366
15.

High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.

Maeng CH, Lee HY, Kim YW, Choi MK, Hong JY, Jung HA, Lee KS, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Um SW, Ahn MJ.

Anticancer Res. 2013 Nov;33(11):5127-33.

PMID:
24222160
16.

Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.

Maeng CH, Yi JH, Lee J, Hong JY, Choi MK, Jung HA, Park JO, Park SH, Park YS, Kang WK, Lim HY.

Anticancer Res. 2013 Oct;33(10):4619-26.

PMID:
24123039
17.

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma.

Kim K, Kim SJ, Maeng CH.

Blood Res. 2013 Sep;48(3):233-4. doi: 10.5045/br.2013.48.3.233. Epub 2013 Sep 25. No abstract available.

18.

Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes.

Ahn HK, Park YH, Lee SJ, Park S, Maeng CH, Park W, Choi DH, Hur SJ, Ahn JS, Im YH.

Springerplus. 2013 Mar 28;2(1):136. doi: 10.1186/2193-1801-2-136. Print 2013 Dec.

19.

Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.

Chang W, Lee SJ, Park S, Choi MK, Hong JY, Kim YS, Maeng CH, Jung HA, Kim S, Lee J.

Melanoma Res. 2013 Apr;23(2):147-51. doi: 10.1097/CMR.0b013e32835efd8d.

PMID:
23411477
20.

Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer.

Park S, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ.

Ann Oncol. 2013 Jun;24(6):1630-9. doi: 10.1093/annonc/mds649. Epub 2013 Feb 7.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk